In particular, the combination of concurrent PD-1 and CTLA-4 blockade holds considerable promise, since PD-1 contributes to T-cell exhaustion primarily in peripheral tissues and within the tumor microenvironment, and CTLA-4 inhibits at earlier point in T-cell activation [7,8]. Here, PDCD1 is linked to neoplasm.